Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Polizzotto

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
The Journal of Infectious Diseases|June 21, 2019
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment TrialChristina Ekenberg, Man-Hung Tang, Adrian G Zucco, et al.
Cell Reports. Medicine|December 3, 2024
Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE studyWin Min Han, Hossain M S Sazzad, Mark Bloch, et al.
Plos Pathogens|July 15, 2024
Sequencing of Kaposi's Sarcoma Herpesvirus (KSHV) genomes from persons of diverse ethnicities and provenances with KSHV-associated diseases demonstrate multiple infections, novel polymorphisms, and low intra-host varianceVickie A Marshall, Elena M Cornejo Castro, Charles A Goodman, et al.
HIV Research & Clinical Practice|August 8, 2022
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D<sup>2</sup>EFTEmmanuelle Papot, Simone Jacoby, Dona Arlinda, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Oncotarget|January 10, 2018
T-cell responses to KSHV infection: a systematic approachRomin Roshan, Nazzarena Labo, Matthew Trivett, et al.
AIDS (London, England)|November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaEmmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Blood|December 9, 2022
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapyAnnatina S Schnegg-Kaufmann, Julie A I Thoms, Golam Sarower Bhuyan, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
The Journal of Infectious Diseases|June 21, 2019
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment TrialChristina Ekenberg, Man-Hung Tang, Adrian G Zucco, et al.
Cell Reports. Medicine|December 3, 2024
Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE studyWin Min Han, Hossain M S Sazzad, Mark Bloch, et al.
Plos Pathogens|July 15, 2024
Sequencing of Kaposi's Sarcoma Herpesvirus (KSHV) genomes from persons of diverse ethnicities and provenances with KSHV-associated diseases demonstrate multiple infections, novel polymorphisms, and low intra-host varianceVickie A Marshall, Elena M Cornejo Castro, Charles A Goodman, et al.
HIV Research & Clinical Practice|August 8, 2022
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D<sup>2</sup>EFTEmmanuelle Papot, Simone Jacoby, Dona Arlinda, et al.
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
Oncotarget|January 10, 2018
T-cell responses to KSHV infection: a systematic approachRomin Roshan, Nazzarena Labo, Matthew Trivett, et al.
AIDS (London, England)|November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaEmmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
HIV Medicine|March 2, 2022
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortiumDathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, et al.
Blood|December 9, 2022
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapyAnnatina S Schnegg-Kaufmann, Julie A I Thoms, Golam Sarower Bhuyan, et al.
Pageof 9